Article Figures & Data
Figures
- Figure 1.
Flow chart showing selection of HIV Research Network (HIVRN) subjects eligible for analyses and final outcome measurement. cART, combination antiretroviral therapy; VL, viral load.
Tables
- Table 1. Subjects Initiating Combination Antiretroviral Therapy in Community- and Hospital-Based Ambulatory Care Settings Within the HIV Research Network from 2000 to 2008
Characteristics Community-Based Care (n = 2314) Hospital-Based Care (n = 12,733) P Value* Age (years), mean (SD) 38.5 (9.2) 38.1 (9.1) <.05 Male sex 1685 (72.8) 9215 (72.4) NS Race/ethnicity White 828 (35.8) 3459 (27.2) <.01 African American/Caribbean 1028 (44.4) 6270 (49.2) Hispanic 386 (16.7) 2727 (21.4) Other 72 (3.1) 277 (2.2) HIV risk factor Heterosexual transmission 995 (43.0) 4487 (35.2) <.01 MSM 975 (42.1) 5094 (40.0) IDU 288 (12.4) 2589 (20.3) Other 37 (1.6) 197 (1.5) Initial CD4 during review period (cells/mm3), mean (SD) 272 (238) 277 (240) NS CD4 before ART (cells/mm3), mean (SD) 266 (237) 238 (201) <.01 Log10 viral load before treatment viral load, mean (SD) 4.3 (0.9) 4.5 (0.9) <.01 Number of outpatient visits per subject over review period, mean (SD) 35.4 (32.4) 32.8 (26.6) NS Type of ART initiated PI only regimen 1200 (51.9) 6758 (53.1) <.01 NNRTI only regimen 724 (31.3) 3713 (29.2) PI and NNRTI 139 (6.0) 1038 (8.2) NRTI only 146 (6.3) 844 (6.6) Other† 105 (4.5) 380 (3.0) Number of days on ART (index regimen‡), mean (SD) 632.7 (524.0) 538.6 (473.2) <.01 Achieved sustained virologic suppression 1646 (71.1) 8416 (66.1) <.01 CD4 increase (cells/mm3), mean (SD) 215 (220) 197 (208) <.01 Data are n (%) unless otherwise indicated.
↵* P values based on Student t test, Wilcoxon rank-sum test, or Pearson χ2.
↵† Regimens that included at least one non-PI/NNRTI antiretroviral medication were labeled “other,” regardless of whether a PI/NNRTI was concurrently prescribed as part of that regimen combination.
↵‡ Index regimen refers to the regimen that contributed to either sustained virologic suppression or treatment failure; for subjects with multiple occurrences of either outcome, the earliest qualifying regimen was counted as the index regimen. Treatment start and stop dates were submitted by HIVRN study sites.
ART, antiretroviral therapy; CD4, Cluster of Differentiation 4; IDU, intravenous drug use; MSM, men who have sex with men; NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside/nucleotide reverse transcriptase inhibitor; NS, not significant; PI, protease inhibitor; SD, standard deviation.
- Table 2. Multivariable-Adjusted Estimates of Sustained Virologic Suppression Among Adults Initiating Combination Antiretroviral Therapy in the HIV Research Network from 2000 to 2008
Variables Adjusted OR* for Sustained Virologic Suppression (95% CI) P Value Setting Hospital-based ambulatory care Reference — Community-based ambulatory care 1.26 (0.73–2.17) NS Age (years) ≥50 Reference — 40–49 0.82 (0.72–0.93) <.01 30–39 0.70 (0.62–0.80) <.01 18–29 0.65 (0.56–0.75) <.01 Sex Male Reference — Female 1.08 (0.98–1.19) NS Race/ethnicity White Reference — African American/Caribbean 0.85 (0.77–0.94) <.01 Hispanic 1.18 (1.05–1.33) <.01 Other 1.31 (0.99–1.73) NS HIV risk factor Heterosexual transmission Reference — MSM 1.14 (1.03–1.27) <.01 IDU 0.82 (0.74–0.91) <.01 Other 0.91 (0.67–1.22) NS CD4 before ART (cells/mm3) <50 Reference — 50–199 1.16 (1.05–1.29) <.01 200–349 1.40 (1.26–1.57) <.01 350–499 1.44 (1.25–1.65) <.01 ≥500 1.27 (1.09–1.47) <.01 Log10 viral load before ART 0.76 (0.73–0.80) <.01 Outpatient visits during review period (n) ≥4 Reference — <4 0.78 (0.57–1.08) NS Type of ART PI only regimen Reference — NNRTI only regimen 1.47 (1.35–1.60) <.01 NNRTI and PI 0.73 (0.64–0.83) <.01 NRTI 0.78 (0.68–0.90) <.01 Other 2.79 (2.15–3.63) <.01 ↵* Multivariate odds ratios include adjustment for care setting, age, sex, race/ethnicity, HIV risk factor, CD4 before antiretroviral therapy (ART), log10 viral load before ART, number of outpatient visits during the review period, and ART regimen type.
ART, antiretroviral therapy; CD4, Cluster of Differentiation 4; CI, confidence interval; IDU, intravenous drug use; MSM, men who have sex with men; NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside/nucleotide reverse transcriptase inhibitor; NS, not significant; OR, odds ratio; PI, protease inhibitor.
